MAnagement of METastatic Disease In Campania (MAMETIC)
MAnagement of METastatic Disease In Campania (MAMETIC)
The MAMETIC Trial represents the first regional epidemiological study that aims to evaluate
 patients living in Campania with metastatic cancer, with the intent to detect different
 prevalence of tumors in the metastatic phase and evaluate the local response to the patient's
 request for assistance.

 Condition or disease: Metastatic disease Intervention/treatment: Radiation Treatment
The MAMETIC Trial is a multicenter, retrospective and prospective observational study and 17
 of 20 RT Centers in Campania joined it.

 1. The retrospective part of the study concerns all patients enrolled with a diagnosis of
 metastatic disease and treated in RT centers of the Campania Region with 3DCRT, IMRT,
 VMAT, SBRT techniques from January 2019 to August 2020. In 2019, it has been enrolled
 12.500 patients in the 17 RT Centers and it is estimated that 20-30% of the above
 mentioned patients had metastasis. Thus, approximately 2.560 patients are expected to be
 enrolled.

 2. The prospective part of the study is going to enroll all metastatic patients eligible
 for palliative RT, treated in RT Centers of the Campania region with 3DCRT, IMRT, VMAT,
 SBRT techniques from September 2020 to September 2025. Considering the RT Centers that
 joined the trial, it is expected to enroll approximately 2.500-4.200 patients per year
 and a total of 12.500-21.000 patients in 5 years.

 The study will last 61 months, divided as follow: 60 months of enrollment phase and up to 1
 month of follow-up for pain and bone metastasis patients. Follow-up will be performed on the
 15th and 30th day after the end of radiation treatment.
Inclusion Criteria:

 -  Patients aged > 18 years resident in Campania Region;

 -  Patients diagnosed with metastatic disease candidates for radiotherapy

 -  Metastatic patients candidates for radiotherapy re-treatment

 -  Oligometastatic patients candidates for radiotherapy; Patients who have given their
 consent

 Exclusion Criteria:

 -  Patients aged < 18 years

 -  Patients who are unable to express consent to sensitive data and radiant treatment